44Sc-DOTA-BN[2-14]NH 2 in comparison to 68Ga-DOTA-BN[2-14]NH 2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?

Applied Radiation and Isotopes

Volumn 70, Issue 12, 2012, Pages 2669-2676

  Koumarianou, E ^a,d   Loktionova, N S ^b   Fellner, M ^b   Roesch, F ^b   Thews, O ^c   Pawlak, D ^a   Archimandritis, S C ^d   Mikolajczak, R ^a  

^a NATIONAL CENTRE FOR NUCLEAR RESEARCH   (Poland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

Bombesin analogue; Gallium 68; GRP receptors affinity; PET tracers; Scandium 44

Indexed keywords

BOMBESIN ANALOGUE; GALLIUM-68; GRP RECEPTORS AFFINITY; PET TRACER; SCANDIUM-44;

BINDING ENERGY; CELL CULTURE; DISEASES; PEPTIDES; RATS; SCANDIUM; TUMORS;

GALLIUM;

DIAGNOSTIC AGENT; GALLIUM TETRAXETAN BOMBESIN[2-14]AMIDE GA 68; GASTRIN RELEASING PEPTIDE RECEPTOR; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; SCANDIUM TETRAXETAN BOMBESIN[2-14]AMIDE SC 44; UNCLASSIFIED DRUG; YTTRIUM 90; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; BOMBESIN; GALLIUM; GASTRIN RELEASING PEPTIDE; RADIOISOTOPE; SCANDIUM; SINGLE HETEROCYCLIC RINGS; TETRAXETAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; COMPARATIVE STUDY; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOISOTOPE DISTRIBUTION; RAT; RECEPTOR AFFINITY; SCINTISCANNING; URINARY EXCRETION; ANIMAL; METABOLISM; METHODOLOGY; PROSTATE TUMOR; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BOMBESIN; CELL LINE, TUMOR; GALLIUM RADIOISOTOPES; GASTRIN-RELEASING PEPTIDE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RATS; SCANDIUM; TISSUE DISTRIBUTION;

EID: 84866784727     PISSN: 09698043     EISSN: 18729800     Source Type: Journal    
DOI: 10.1016/j.apradiso.2012.08.004     Document Type: Article

References (23)

1. 68Ga-DOTATOC. Nucl. Med. Biol. 2008, 35:721-724.
2. Barone R., Borson-Chazot F., Valkema R., Walrand S., Chauvin F., Gogou L., et al. Patient-specific dosimetry in predicting renal toxicity with 90YDOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J. Nucl. Med. 2005, 46(Suppl. 11):99S-106S.
3. 44Sc-based PET-radiopharmaceuticals. Radiochim. Acta 2010, 98:149-156.
4. 99mTc-labeled bombesin-like peptides for early cancer detection. Anticancer Res. 2006, 26(1A):435-438.
5. 44Sc radio-nuclide with liquid xenon as detection medium. Nucl. Instrum. Methods Phys. Res. A 2007, 571:142-145.
6. Kolsky K.L., Joshi V., Mausner L.F., Srivastava S.C. Radiochemical purification of no-carrier added Scandium-47 for radioimmunotherapy. Appl. Radiat. Isot. 1998, 49:1541-1549.
7. 177Lu: in vitro and in vivo evaluation. Nucl. Med. Biol. 2009, 36:591-603.
8. natGa-DOTA-TATE. Nucl. Med. Rev. 2011, 14(2):85-89.
9. 44Sc-DOTATOC. J. Labelled Compds. Radiopharm. 2009, 52(1):S490.
10. Mausner L.F., Kolsky K.L., Joshi V., Srivastava S.C. Radionuclide development at BNL for nuclear medicine therapy. Appl. Radiat. Isot. 1998, 49:285-294.
11. Mausner, L.F., Joshi, V., Kolsky, K.L., Meinken, G.E., Mease, R.C., Sweet, M.P., Srivastava, S.C., 1995. Evaluation of chelating agents for radioimmunotherapy with scandium-47. J. Nucl. Med. 36, 104 (Suppl. 5), In: Proceeding of the meeting of the Society of Nuclear Medicine. Minneapolis, United States, pp. 104, 423.
12. Majkowska-Pilip A., Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J. Inorg. Biochem. 2011, 105:313-320.
13. 44Sc for clinical application. Appl. Radiat. Isot. 2010, 68:1636-1641.
14. 44Sc. J. Labeled Compds. Radiopharm. 2009, 52(1):S490.
15. Panigone S., Nunn A.D. Lutetium-177 labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy. Q J. Nucl. Med. Mol. Imaging 2006, 5(4):310-321.
16. Rösch F., (Russ) Knapp F.F. Radiochemistry and radiopharmaceutical chemistry in life science. Handbook of Nuclear Chemistry 2003, vol. 4:81-118. Kluver Academic Publishers, Dordrecht/Boston/London.
17. 68Ga radiopharmaceutical Chemistry. Curr. Top. Med. Chem. 2010, 10:1633-1668.
18. Reubi J.C., Schar J.C., Waser B., Wenger S., Heppeler A., Schmitt J.S., Maecke H.R. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 2000, 27:273-282.
19. Smith C.J., Volkert W.A., Hoffman T.J. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl. Med. Biol. 2004, 30:861-868.
20. 4DOTA): Structural overview and analyses on structure-stability relationships. Coord. Chem. Rev. 2009, 253:1906-1925.
21. Welch M.J., McCarthy T.J. The potential role of generator-produced radiopharmaceuticals in clinical PET. J. Nucl. Med. 2000, 41(2):315-317.
22. 68Ga for medical application. J. Nucl. Med. 2007, 48:1741-1748.
23. Zhang H., Schumacher J., Waser B., Wild D., Eisenhut M., Reubi J.C. DOTA-PESIN, a DOTA conjugate bombesin derivative designed for the treatment of bombesin receptor - positive tumours. Eur. J. Nucl. Med. Mol. Imaging 2007, 34:1198-1208.